MMP12
Macrophage metalloelastase
As of the edition of 20 October 2026, MMP12 (macrophage metalloelastase, UniProt P39900) has 3 drugs tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P39900
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 86
- Disease areas
- Digestive system; Lungs and airways; Infections; Cancer; Inherited and neonatal
- Registered trials of its drugs
- 13
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| AZD-1236 | Went quiet | Phase 2 | none listed |
| CTS-1027 | Went quiet | Phase 2 | none listed |
| Aderamastat | Stopped | Phase 3 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Foresee Pharmaceuticals | Route A |
| AstraZeneca | Route A |
| Conatus Pharmaceuticals | Route A |
The other 0 companies at MMP12
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at MMP12, ranked, with the facts behind eachRequest access. Nothing is shown until you do.